• Malaise D, Houillier C, Touitou V, Choquet S, Maloum K, Le Garff-Tavernier M, Davi F, Vincent-Salomon A, Feuvret L, Hoang-Xuan K, Cassoux N, Soussain C. LOC network and the ERN-EuroBloodNet. Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up. Curr Opin Oncol. 33:420-431, 2021. DOI: 10.1097/CCO.0000000000000776.

  • Soussain C, Malaise D, Cassoux N. Primary vitreoretinal lymphoma: A diagnostic and management challenge. Blood. 2021 May 25:blood.2020008235. DOI: 10.1182/blood.2020008235.  

  • Orlhac F, Eertink JJ, Cottereau AS, Zijlstra JM, Thieblemont C, Meignan M, Boellaard R, Buvat I. A guide to ComBat harmonization of imaging biomarkers in multi center studies. J Nucl Med. in press, 2021. 

  • Jehan-Besson S, Clouard R, Boddaert N, Grill J, Frouin F. Optimization of a Shape Metric Based on Information Theory Applied to Segmentation Fusion and Evaluation in Multimodal MRI for DIPG Tumor Analysis. Proceedings of 5th International Conference GSI 2021: 772-780.

  • Cottereau AS, Meignan M, Nioche C, Clerc J, Chartier L, Vercellino L, Casasnovas O, Thieblemont C, Buvat I. New approaches in characterisation of lesions dissemination in DLBCL patients on baseline PET/CT. Cancers. 13:3998, 2021. DOI: https://doi.org/10.3390/cancers13163998 

  • Seban RD, Donnadieu A, Journo G, Bidard FC, Richard C, Rouzier R, Champion L.18F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab. Diagnostics. 11:1353, 2021. DOI: https://doi.org/10.3390/diagnostics11081353

  • Seban RD, Synn S, Muneer I, Champion L, Schwartz LH, Dercle L. Don't overlook spleen glucose metabolism on [18F]-FDG PET/CT for cancer drug discovery and development. Curr Cancer Drug Targets. DOI: 10.2174/1568009621666210720143826. in press, 2021.

  • Seban RD, Assié JB, Giroux-Leprieur E, Massiani MA, Bonardel G, Chouaid C, Deleval N, Richard C, Mezquita L, Girard N, Champion L. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. Lung Cancer. 159: 45-55, 2021. DOI: https://doi.org/10.1016/j.lungcan.2021.06.024 

  • Wallis D, Soussan M, Lacroix M, Akl P, Duboucher C, Buvat I. An FDG-PET/CT deep learning method for fully automated detection of pathological mediastinal lymph nodes in lung cancer patients. Eur J Nucl Med Mol Imaging. in press, 2021.

  • Orlhac F, Nioche C, Klyuzhin I, Rahmim A, Buvat I. Radiomics in PET imaging - A practical guide for newcomers. PET Clin. in press, 2021. 

  • Seban RD, Champion L, Yeh R, Schwartz LH, Dercle L. Assessing immune response upon systemic RNA vaccination on [18F]-FDG PET/CT for COVID-19 vaccine and then for immune-oncology? (letter to the Editor). Eur J Nucl Med Mol Imaging. in press, 2021. DOI: 10.1007/s00259-021-05468-z

  • Seban RD, Champion L, Muneer I, Synn S, Schwartz LH, Dercle L. Potential theranostic role of bone marrow glucose metabolism on baseline [18F]-FDG PET/CT in metastatic melanoma (letter to the Editor). J Nucl Med. In press, 2021. DOI: 10.2967/jnumed.121.262361

  • Dumas JL, Dal R, Zefkili S, Robilliard M, Losa S, Birba I, Vu-Bezin J, Beddok A, Calugaru V, Dutertre G, De Marzi L. Addressing the dosimetric impact of bone cement and vertebroplasty in stereotactic body radiation therapy. Phys Med. 202185:42-49. DOI: 10.1016/j.ejmp.2021.04.023.

  • Costa E, Richir T, Robilliard M, Bragard C, Logerot C, Kirova Y, Fourquet A, De Marzi L. Assessment of a conventional volumetric-modulated arc therapy knowledge-based planning model applied to the new Halcyon© O-ring linac in locoregional breast cancer radiotherapy. Phys Med. 86:32-43. 2021. DOI: 10.1016/j.ejmp.2021.05.022.  

  • Orlhac F, Buvat I. Comment on Ibrahim, A. et al. The Effects of In-Plane Spatial Resolution on CT-Based Radiomic Features’ Stability with and without ComBat Harmonization. Cancers. In press, 2021. DOI: https://doi.org/10.3390/cancers13123037 

  • Seban RD, Vermersch C, Champion L, Bonsang B, Roger A, Ghidaglia J. Immune-Related Erythema Nodosum Mimicking in Transit Melanoma Metastasis on [18F]-FDG PET/CT. Diagnostics. 11: 747, 2021. DOI: https://doi.org/10.3390/diagnostics11050747

  • Aide N, Lasnon C, Kesner A, Levin C, Buvat I, Iagaru A, Hermann K, Badawi RD, Cherry SR, Bradley KM, McGowan DR. New PET technologies: embracing progress and pushing the limits. Eur J Nucl Med Mol Imaging. 48: 2711–2726, 2021. DOI: https://doi.org/10.1007/s00259-021-05390-4

  • Beyer T, Bailey DL, Birk UJ, Buvat I, Catana C, Cheng Z, Fang Q, Giove F, Kuntner C, Laistler E, Moscato F, Nekolla SG, Rausch I, Ronen I, van Elmpt W, Saarakkala S, Thielemans K, Moser E. Medical Physics and Imaging – A timely perspective. Frontiers in Physics. 2021. sous presse. DOI: https://doi.org/10.3389/fphy.2021.634693

  • Seban RD, Champion L, Deleval N, Richard C, Provost C. Immune Response Visualized In Vivo by [18F]-FDG PET/CT after COVID-19 Vaccine. Diagnostics. 11: 676, 2021. DOI: https://doi.org/10.3390/diagnostics11040676

  • Seban RD, Rouzier R, Latouche A, Deleval N, Guinebretiere JM, Buvat I, Bidard FC, Champion L. Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer. Eur J Nucl Med Mol Imaging. in press, 2021. DOI: https://doi.org/10.1007/s00259-021-05322-2 

  • Schneider T, De Marzi L, Patriarca A and Prezado Y. Monte Carlo Comparison of Proton and Helium-ion Minibeam Generation Techniques. Front. Phys. 9:595721, 2021. DOI: https://doi.org/10.3389/fphy.2021.595721

  • Loto O, Zahradnik I, Leite AM, De Marzi L, Tromson D, Pomorski M. Simultaneous measurements of dose and microdosimetric spectra in a clinical proton beam using a scCVD diamond membrane microdosimeter. Sensors (Basel). 21:1314, 2021. DOI: https://www.mdpi.com/1424-8220/21/4/1314

  • Leduc A, Chaouni S, Pouzoulet F, De Marzi L, Megnin-Chanet F, E Corre, Stefan D, Habrand JL, Sichel F, Laurent C. Differential normal skin transcriptomic response in total body irradiated mice exposed to scattered versus scanned proton beams. Sci Rep 11, 5876, 2021. DOI: https://doi.org/10.1038/s41598-021-85394-0

  • Buvat I, Orlhac F. The T.R.U.E. checklist for identifying impactful AI-based findings in nuclear medicine: is it True? Is it Reproducible? Is it Useful? Is it Explainable? J Nucl Med. 62: 752-754, 2021. DOI: https://doi.org/10.2967/jnumed.120.261586 

  • Prezado Y, Hirayama R, Matsufuji N, Inaniwa T, Martínez-Rovira I, Seksek O, Bertho A, Koike S, Labiod D, Pouzoulet F, Polledo L, Warfving N, Liens A, Bergs J, Shimokawa T. A potential renewed use of very heavy ions for therapy: Neon minibeam radiation therapy. Cancers. 13:1356, 2021. DOI: 10.3390/cancers13061356

  • Weber M, Kersting D, Umutlu L, Schäfers M, Rischpler C, Fendler WP, Buvat I, Herrmann K, Seifert R. Just another ‘Clever Hans’? Neural Networks and FDG PET‑CT to predict the Outcome of Patients with Breast Cancer. Eur J Nucl Med Mol Imaging. in press, 2021.

  • Seban RD, Champion L, Schwartz LH, Dercle L. Spleen glucose metabolism on [F-18]-FDG PET/CT: a dynamic double-edged biomarker predicting outcome in cancer patients (letter to the Editor). Eur J Nucl Med Mol Imaging. in press, 2021. DOI: 10.1007/s00259-020-05126-w

  • Perret P, Slimani L, Barone-Rochette G, Vollaire J, Briat A, Ahmadi M, Henri M, Desruet MD, Clerc R, Broisat A, Riou L, Boucher F, Frouin F, Djaileb L, Calizzano A, Vanzetto G, Fagret D, Ghezzi, C. Preclinical and clinical evaluation of a new method to assess cardiac insulin resistance using nuclear imaging. Journal of Nuclear Cardiology. In press.

  • Chaouni S, Leduc A, Pouzoulet F, De Marzi L, Megnin-Chanet F, Stefan D, Habrand J-L, Sichel F, Laurent C. Biological Effects of Scattered Versus Scanned Proton Beams on Normal Tissues in Total Body Irradiated Mice: Survival, Genotoxicity, Oxidative Stress and Inflammation. Antioxidants. 9:1170, 2020.

  • Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, Vercellino L, Casasnovas O, Thieblemont C, Buvat I. Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT. Ann Oncol. 32: 404-411, 2021. DOI: 10.1016/j.annonc.2020.11.019

  • Saint Martin MJ, Orlhac F, Akl P, Khalid F, Nioche C, Buvat I, Malhaire C, Frouin F. A radiomics pipeline dedicated to Breast MRI: validation on a multi-scanner phantom study. MAGMA. 34: 355-366, 2021. 

  • Weber WA, Czernin J, Anderson CJ, Badawi RD, Bartel H, Bengel F, Bodei L, Buvat I, DiCarli M, Graham MM, Grimm J, Herrmann K, Kostakoglu L, Lewis JS, Peterson T, Schelbert H, Schoder H, Siegel BA, Strauss HW, Townsend DM. The future of nuclear medicine, molecular imaging, and theranostics. J Nucl Med. 61: 263S-272S, 2020. DOI: 10.2967/jnumed.120.254532

  • Sundar LKS , Muzik O, Buvat I, Bidaut L, Beyer T. Potentials and caveats of artificial intelligence in hybrid imaging. Methods. 188: 4-19, 2021. DOI: 10.1016/j.ymeth.2020.10.004

  • Orlhac F, Lecler A, Savatovski J, Goya-Outi J, Nioche C, Charbonneau F, Ayache N, Frouin F, Duron L, Buvat I. How can we combat multicenter variability in MR radiomics? Validation of a correction procedure. Eur Rad. 31: 2272-2280, 2021. DOI: 10.1007/s00330-020-07284-9

  • Lamirault C, Doyère V, Juchaux M, Pouzoulet F, Labiod D, Dendale R, Patriarca A, Nauraye C, Le Dudal M, Jouvion G, Hardy D, Massioui NE, Prezado Y. Short and long term evaluation of the impact of proton mini beam radiation therapy on motor, emotional and cognitive functions. Sci Rep. 10:13511, 2020. DOI: 10.1038/s41598-020-70371-w

  • Capobianco N, Meignan M, Cottereau AS, Vercellino L, Sibille L, Spottiswoode B, Zuehlsdorff S, Casasnovas O, Thieblemont C, Buvat I. Deep learning FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma. J Nucl Med. 62: 30-36, 2021. DOI: 10.2967/jnumed.120.242412

  • Wimberley C, Nguyen DL, Truillet C, Peyronneau MA, Gulhan Z, Tonietto M, Boumezbeur F, Boisgard R, Chalon S, Bouilleret V, Buvat I. Longitudinal mouse-PET imaging: a reliable method for estimating binding parameters without a reference region or blood sampling. Eur J Nucl Med Mol Imaging. 47:2589-2601, 2020. DOI: 10.1007/s00259-020-04755-5

  • Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, Ashrafinia S, Bakas S, Beukinga RJ, Boellaard R, Bogowicz M, Boldrini L, Buvat I, Cook GJR, Davatzikos C, Depeursinge A, Desseroit MC, Dinapoli N, Dinh CV, Echegaray V, El Naqa I, Fedorov AY, Gatta R, Gillies RJ, Goh V, Guckenberger M, Götz M, Ha SM, Hatt M, Isensee F, Lambin P, Leger S, Leijenaar RTH, Lenkowicz J, Lippert F, Losnegård A, Maier-Hein KH, Morin O, Müller H, Napel S, Nioche C, Orlhac F, Pati S, Pfaehler EAG, Rahmim A, Rao AUK, Scherer J, Siddique MM, Sijtsema NM, Fernandez JS, Spezi E, Steenbakkers RJHM, Tanadini-Lang S, Thorwarth D, Troost EGC, Upadhaya T, Valentini C, van Dijk LV, van Griethuysen J, van Velden FHP, Whybra P, Richter C, Löck S. The Image Biomarker Standardization Initiative: standardized quantitative radiomics for highthroughput image-based phenotyping. Radiology. 295:328-338, 2020. DOI: 10.1148/radiol.2020191145

  • Lemaître S, Poyer F, Fréneaux P, Leboucher S, Doz F, Cassoux N, Thomas CD. Low retinal toxicity of intravitreal carboplatin associated with good retinal tumour control in transgenic murine retinoblastoma. Clin Exp Ophthalmol. 48:500-511, 2020. DOI: 10.1111/ceo.13711

  • Tanaka I, Chakraborty A, Saulnier O, Benoit-Pilven C, Vacher S, Labiod D, Lam EWF, Bièche I, Delattre O, Pouzoulet F, Auboeuf D, Vagner S, Dutertre M. ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. Nucleic Acids Res. 2020. DOI: 10.1093/nar/gkz1213

  • Lacroix M, Frouin F, Dirand AS, Nioche C, Orlhac F, Bernaudin JF, Brillet PY, Buvat I. Correction for magnetic field inhomogeneities and normalization of voxel values are needed to better reveal the potential of MR radiomic features in lung cancer. Front Oncol. doi: 10.3389/fonc.2020.00043, 2020. DOI: 10.3389/fonc.2020.00043

  • Cottereau AS, Nioche C, Dirand AS, Clerc J, Morschhauser F, Casasnovas O, Meignan MA, Buvat I. 18F-FDG-PET dissemination features in diffuse large B cell lymphoma are predictive of outcome. J Nucl Med. 61. 40-45, 2020. DOI: 10.2967/jnumed.119.229450

  • Provost C, Mammar H, Belly-Poinsignon A, Madar O, Champion L. Pharmacokinetic Analysis of [18F]FAZA Dynamic PET Imaging Acquisitions for Highlighting Sacrum Tumor Profiles. Clin Nucl Med. 45:e36-e38, 2020. DOI: 10.1097/RLU.0000000000002813

  • Boughdad S, Nioche C, Orlhac F, Jehl L, Champion L, Buvat I. Influence of age on radiomic features in 18F-FDG PET in normal breast tissue and in breast cancer tumors. Oncotarget. 9:30855-30868, 2018. DOI: 10.18632/oncotarget.25762

  • Goutal S, Gerstenmayer M, Auvity S, Caillé F, Mériaux S, Buvat I, Larrat B, Tournier N. Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib. J Control Release. 292:210-220, 2018.

  • Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, Barakat C, Soussan M, Frouin F, Buvat I. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 78:4786-4789, 2018. version PDF

  • Reuzé S, Schernberg A, Orlhac F, Sun R, Dercle L, Deutsch E, Buvat I, Robert C. Radiomics in Nuclear Medicine applied to Radiation Therapy: methods, pitfalls and challenges. Int J Radiat Oncol Biol Phys. 102:1117-1142, 2018. version PDF. DOI: 10.1016/j.ijrobp.2018.05.022

  • Auvity S, Caillé F, Marie S, Wimberley C, Bauer M, Langer O, Buvat I, Goutal S, Tournier N. P-glycoprotein (ABCB1) inhibits the influx and increases the efflux of 11C-metoclopramide across the blood-brain barrier: a PET study on non-human primates. J Nucl Med. 59:1609-1615, 2018.

  • Goya-Outi J, Orlhac F, Calmon R, Alentorn A, Nioche C, Philippe C, Puget S, Boddaert N, Buvat I, Grill J, Frouin V, Frouin F. Computation of reliable textural indices from multimodal brain MRI: suggestions based on a study of patients with diffuse intrinsic pontine glioma. Phys Med Biol. 63:105003, 2018. version PDF

  • Cottereau AS, Buvat I, Kanoun S, Versari A, Casasnovas O, Chauvie S, Clerc J, Gallamini A, Meignan M. Is there an optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma? Eur J Nucl Med Mol Imaging. 45:1463-1464, 2018. version PDF

  • Nguyen DL, Wimberley C, Truillet C, Jego B, Caillé F, Pottier G, Boisgard R, Buvat I, Bouilleret V. Longitudinal positron emission tomography imaging of glial cell activation in a mouse model of mesial temporal lobe epilepsy: Toward identification of optimal treatment windows. Epilepsia. 59:1234-1244, 2018. version PDF

  • Orlhac F, Boughdad S, Philippe C, Stalla-Bourdillon H, Nioche C, Champion L, Soussan M, Frouin F, Frouin V, Buvat I. A post-reconstruction harmonization method for multicenter radiomic studies in PET. J Nucl Med. 59:1321–1328, 2018. version PDF

  • Kucharczak F, Loquin K, Buvat I, Strauss O, Mariano-Goulart D. Interval-based reconstruction for uncertainty quantification in PET. Phys Med Biol. 63: 035014, 2018. version PDF

  • Wimberley C, Lavisse S, Peyronneau MA, Brulon V, Leroy C, Remy P, Stankoff B, Buvat I, Bottlaender M. The impact of endothelial TSPO on the quantification of 18F-DPA714 in the healthy human. J Nucl Med. 59: 307-314, 2018. version PDF

  • Schernberg A, Reuzé S, Orlhac F, Buvat I, Dercle L, Sun R, Limkin E, Escande A, Haie-Meder C, Deutsch E, Robert C. A score combining baseline neutrophilia and the SUVpeak of the primary tumor on FDG-PET predicts outcome in locally advanced cervical cancer. Eur J Nucl Med Mol Imaging. 45:187-195, 2018. version PDF

  • Saba W, Goutal S, Auvity S, Kuhnast B, Coulon C, Kouyoumdjian V, Buvat I, Leroy C, Tournier N. Imaging the neuroimmune response to alcohol exposure in adolescent baboons: a TSPO PET study using 18F-DPA-714. Addict Biol. 23:1000-1009, 2018.

  • Vandenberghe ME, Souedet N, Hérard AS, Ayral AM, Letronne F, Balbastre Y, Sadouni E, Hantraye P, Dhenain M, Frouin F, Lambert JC, Delzescaux T. Voxel-Based Statistical Analysis of 3D Immunostained Tissue Imaging. Front Neurosci. 12:754, 2018.

  • Lazard DS, Bergeret-Cassagne H, Lefort M, Leenhardt L, Russ G, Frouin F, Trésallet C. Transcutaneous Laryngeal Ultrasonography for Laryngeal Immobility Diagnosis in Patients with Voice Disorders After Thyroid/Parathyroid Surgery. World J Surg. 42:2102-2108, 2018.

  • Provost C, Prignon A, Rozenblum-Beddok L, Bruyer Q, Dumont S, Merabtene F, Nataf V, Bouteiller C, Talbot JN. Comparison and evaluation of two RGD peptides labelled with 68Ga or 18F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma. Oncotarget. 9:19307-19316, 2018.

  • Buvat I, Orlhac F. The dark side of radiomics: on the paramount importance of publishing negative results. J Nucl Med. 60:1543-1544, 2019. DOI: 10.2967/jnumed.119.235325

  • Dirand AS, Frouin F, Buvat I. A downsampling strategy to assess the predictive value of radiomic features. Sci Rep. 9:17869, 2019. version en ligne. DOI: 10.1038/s41598-019-54190-2

  • Laurent C, Ricard L, Fain O, Buvat I, Adedjouma A, Soussan M, Mekinian A. PET/MRI in large-vessel vasculitis: clinical value for diagnosis and assessment of disease activity. Sci Rep. 9:12388, 2019. version en ligne. DOI: 10.1038/s41598-019-48709-w

  • De Marzi L, Da Fonseca A, Moignier C, Patriarca A, Goudjil F, Mazal A, Buvat I, Hérault J. Experimental characterisation of a proton kernel model for pencil beam scanning techniques. Phys Med. 64:195-203, 2019. version PDF. DOI: 10.1016/j.ejmp.2019.07.013

  • Veit-Haibach I, Buvat I, Herrmann K. AI and Radiomics in Nuclear Medicine and Hybrid Imaging: potential, challenges and clinical role. Eur J Nucl Med Mol Imaging. 46: 2627-2629, 2019. DOI: 10.1007/s00259-019-04395-4

  • Orlhac F, Frouin F, Nioche C, Ayache N, Buvat I. Validation of a method to compensate multicenter effects affecting CT radiomic features. Radiology. 91:53-59, 2019. DOI: 10.1148/radiol.2019182023

  • Goldfarb L, Duchemann B, Chouahnia K, Zelek L, Soussan M. Monitoring anti-PD-L1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res.9:8, 2019. version en ligne 

  • Prignon A, Provost C, Alshoukr F, Wendum D, Couvelard A, Barbet J, Forgez P, Talbot JN, Gruaz-Guyon A. Preclinical Evaluation of 68Ga-DOTA-NT-20.3: A Promising PET Imaging Probe To Discriminate Human Pancreatic Ductal Adenocarcinoma from Pancreatitis. Mol Pharm. 16:2776-2784, 2019.

  • Provost C, Rozenblum-Beddok L, Nataf V, Merabtene F, Prignon A, Talbot JN. [68Ga]RGD Versus [18F]FDG PET Imaging in Monitoring Treatment Response of a Mouse Model of Human Glioblastoma Tumor with Bevacizumab and/or Temozolomide. Mol Imaging Biol. 21:297-305, 2019.

  • Cassou-Mounat T, Champion L, Bozec L, Laurence V, Huchet V, Luporsi M, Jehanno N. Primary and Secondary Breast Angiosarcoma: FDG PET/CT Series. Clin Nucl Med. 44:e33-e35, 2019.

  • Bando-Delaunay A, Luporsi M, Huchet V, Cassou-Mounat T, Jehanno N. A Case of Sarcoidosis After Lymphoma. Clin Nucl Med. 44:646-647, 2019.

  • Jehanno N, Cassou-Mounat T, Mammar H, Luporsi M, Huchet V. 18F-Choline PET/CT Imaging for Intracranial Hemangiopericytoma Recurrence. Clin Nucl Med. 44:e305-e307, 2019.

  • Cassou-Mounat T, Luporsi M, Huchet V, Jehanno N. Gallbladder Metastasis From Conjunctival Melanoma. Clin Nucl Med. 44:e107-e109, 2019.